{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:19:58Z","timestamp":1791357598467,"version":"4.3.1"},"reference-count":16,"publisher":"Royal College of Psychiatrists","issue":"6","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"unspecified","delay-in-days":6608,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1999,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People prescribed clozapine for treatment-resistant schizophrenia have mandatory haematological monitoring through a case register for identifying reversible neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To quantify risk factors for agranulocytosis in subjects receiving clozapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Data from 12 760 subjects registered to receive clozapine from January 1990 to April 1997 were analysed. Risk factors for agranulocytosis were quantified using a Cox proportional-hazards regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The risk for agranulocytosis in Asian subjects was 2.4 times that in Caucasians (\n                      <jats:italic>P<\/jats:italic>\n                      =0.03). There was an age-related increase in risk of 53% per decade (\n                      <jats:italic>P<\/jats:italic>\n                      =0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The case register yielded valuable information for guiding research into the causes of the haematological reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/bjp.175.6.576","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T01:41:36Z","timestamp":1224034896000},"page":"576-580","source":"Crossref","is-referenced-by-count":244,"title":["Active monitoring of 12760 clozapine recipients in the UK and Ireland"],"prefix":"10.1192","volume":"175","author":[{"given":"Janet","family":"Munro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Arana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kerwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"S0007125000263368_ref9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1176\/ps.47.1.52","article-title":"Effects of the Clozapine National Registry System on incidence of deaths related to agranulocytosis","volume":"47","author":"Honigfeld","year":"1996","journal-title":"Psychiatric Services"},{"key":"S0007125000263368_ref7","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.173.1.11"},{"key":"S0007125000263368_ref5","first-page":"69","volume-title":"Statistical Methods in Cancer Research. Volume II: The Design and Analysis of Cohort Studies","author":"Breslow","year":"1987"},{"key":"S0007125000263368_ref11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.163.2.183"},{"key":"S0007125000263368_ref10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/ajp.152.2.183","article-title":"Reduction of suicidally during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk\u2013benefit assessment","volume":"152","author":"Meitzer","year":"1995","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000263368_ref15","volume-title":"SAS\/STAT. Version 6.12","year":"1996"},{"key":"S0007125000263368_ref3","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.169.4.483"},{"key":"S0007125000263368_ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"S0007125000263368_ref12","doi-asserted-by":"publisher","DOI":"10.1177\/070674379103600401"},{"key":"S0007125000263368_ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb06486.x"},{"key":"S0007125000263368_ref13","volume-title":"Mortality Statistics: General, England and Wales, 1993, 1994, 1995","year":"1995"},{"key":"S0007125000263368_ref14","volume-title":"Review of the Registrar General on Deaths in England and Wales, 1993\u20131995","year":"1997"},{"key":"S0007125000263368_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(92)90040-C"},{"key":"S0007125000263368_ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1991.tb03132.x"},{"key":"S0007125000263368_ref6","volume-title":"StatXact-3 for Windows","year":"1995"},{"key":"S0007125000263368_ref2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1192\/S0007125000296335","article-title":"Disabilities and circumstances of schizophrenic patients \u2013 a follow-up study. V: Cause of death","volume":"159","author":"Anderson","year":"1991","journal-title":"British Journal of Psychiatry"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000263368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T15:54:33Z","timestamp":1557417273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000263368\/type\/journal_article"}},"subtitle":["Beyond pharmacovigilance"],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["S0007125000263368"],"URL":"https:\/\/doi.org\/10.1192\/bjp.175.6.576","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}